Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40
Pliant Therapeutics Analyst Ratings
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential
Leerink Partners Initiates Pliant Therapeutics(PLRX.US) With Buy Rating, Announces Target Price $33
Oppenheimer Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $45
Oppenheimer Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
CCORF Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $43
Pliant Therapeutics Analyst Ratings
Pliant Therapeutics: A Buy Rating on Robust Clinical Progress and Promising Drug Prospects
Pliant Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Allogene Therapeutics (ALLO)
TD Cowen Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
Piper Sandler Sticks to Its Buy Rating for Pliant Therapeutics (PLRX)
Pliant Therapeutics Analyst Ratings
TD Cowen Remains a Buy on Pliant Therapeutics (PLRX)
Pliant Therapeutics Analyst Ratings
Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)
Pliant Therapeutics Analyst Ratings
TD Cowen Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)